1. Home
  2. GRFS

GRFS

Grifols S.A.

Logo Grifols S.A.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Founded: 1940 Country:
Spain
Spain
Employees: N/A City: N/A
Market Cap: 4.4B IPO Year: 2006
Target Price: $10.50 AVG Volume (30 days): 2.2M
Analyst Decision: Sell Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.10 EPS Growth: -70.97
52 Week Low/High: $5.30 - $12.15 Next Earning Date: 07-28-2022
Revenue: $7,324,418,889 Revenue Growth: 8.71%
Revenue Growth (this year): 9.99% Revenue Growth (next year): 7.32%

Share on Social Networks: